10
total announcements
ALPA.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 20 Oct 2026
Market Cap
₹110 Cr
P/E (TTM)
31.1
P/E (Forward)
9.9
EPS (TTM)
₹1.68
52W Low
₹46.10
52W High
₹93.85
Dividend Yield
0.00%
Beta
0.91
Price / Book
0.6
Debt / Equity
1.3
Revenue (TTM)
₹111 Cr
Gross Margin
25.54%
Operating Margin
-19.54%
Alpa Laboratories Ltd
Alpa Laboratories Ltd submitted a certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018, confirming the dematerialization of securities up to September 30, 2026, and listing of securities on the stock exchange.
Alpa Laboratories Ltd
Alpa Laboratories Ltd has submitted the Exchange a copy of Scrutinizer's Report of its 38th Annual General Meeting, which was held on September 30, 2026, through video conference.
Alpa Laboratories Ltd
Alpa Laboratories Ltd held its 38th Annual General Meeting (AGM) on September 30, 2026, through video conference. The meeting approved the audited standalone and consolidated financial statements for the year ended March 31, 2026, and appointed a new director. The meeting also approved the remuneration of the cost auditors and the appointment of an independent director. Additionally, the meeting approved the grant of loans, guarantees, security, and investments up to Rs. 160 crores.
Alpa Laboratories Ltd
Alpa Laboratories Ltd has announced the closure of its trading window for designated persons and their immediate relatives from October 1, 2026, until 48 hours after the unaudited financial results for the half year ending September 30, 2026, become generally available information.
Alpa Laboratories Ltd
Alpa Laboratories Ltd has announced its Annual Report for the Financial Year Ended March 31, 2026, and has convened its 38th Annual General Meeting (AGM) on September 30, 2026, through video conference. The report includes the audited standalone and consolidated financial statements, reports of the board of directors and auditors, and other corporate information.
Alpa Laboratories Ltd
Alpa Laboratories Ltd has announced its unaudited standalone and consolidated financial results for the quarter ended June 2026, with a net profit of Rs. 103.84 crore and a basic and diluted earnings per share of Rs. 0.52.
Alpa Laboratories Ltd
Alpa Laboratories Ltd clarified the date of its board meeting, stating it will be held on 13th August 2026 at 3:00 PM, correcting a typographical error in the initial announcement.
Alpa Laboratories Ltd
Alpa Laboratories Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 14/08/2026 to consider and approve the standalone and consolidated unaudited financial results for the quarter ended on 30th June, 2026.
Alpa Laboratories Ltd
Alpa Laboratories Ltd has informed the exchanges that it has accorded approval in principle for exploring the proposed promotion and incorporation of an overseas company in the Federal Republic of Nigeria, Alpa Biopharm Limited, in association with Blueseal Pharmaceuticals Limited, Nigeria.
Alpa Laboratories Ltd
Alpa Laboratories Ltd announced the cessation of Ms. Jyoti Jain as an Independent Director upon completion of her tenure, effective from close of business hours on 21 July 2026.